Evidence map›Paper›PMID 38915400›Full record

ArticleFrontiers in immunology2024

Healthcare resource utilization patterns in psoriasis patients using biologic and conventional treatments in Finland.

Aino Vesikansa, Juha Mehtälä, Jaakko Aaltonen, Riikka Konttinen, Kaisa Tasanen, Laura Huilaja

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Aino VesikansaMedEngine Oy, Helsinki, Finland.
Juha MehtäläMedEngine Oy, Helsinki, Finland.
Jaakko AaltonenAbbVie Oy, Helsinki, Finland.
Riikka KonttinenAbbVie Oy, Helsinki, Finland.
Kaisa TasanenDepartment of Dermatology and Medical Research Center, Oulu University Hospital, PEDEGO Research Unit, University of Oulu, Oulu, Finland.
Laura HuilajaDepartment of Dermatology and Medical Research Center, Oulu University Hospital, PEDEGO Research Unit, University of Oulu, Oulu, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction and aim: Psoriasis vulgaris is associated with a significant healthcare burden, which increases over time as the disease progresses. The aim of this retrospective, population-based registry study was to characterize healthcare resource utilization (HCRU) in patients with psoriasis using biologics and oral immunosuppressants (conventionals) in Finland. Materials and methods: The study cohort included all patients with a diagnosis of psoriasis vulgaris in the secondary healthcare setting between 2012-2018, who initiated a biologic (n=1,297) or conventional (n=4,753) treatment between 2013-2017. Data on primary and secondary HCRU were collected from nationwide healthcare registries. Results: The results indicated a remarkable decrease in contacts with a dermatologist after the treatment initiation among patients starting biologic (mean annual number of contacts 5.4 per person before and 2.3 after the initiation), but not conventional (3.3 and 3.2) treatment. For conventional starters there was a high level of contacts with a dermatologist surrounding times of treatment switching, which was not observed for biologic starters. Conclusion: Overall, primary and other secondary care contacts did not decrease after the initiation or switch of treatment. The results highlight the importance of thorough consideration of the most optimal treatment alternatives, considering the overall disease burden to patients and healthcare systems.

Indexed as

Biological ProductsPatient Acceptance of Health CarePsoriasisRegistriesAdolescentAdultAgedFemaleFinlandHealth ResourcesHumansImmunosuppressive AgentsMaleMiddle AgedRetrospective StudiesYoung AdultBiological ProductsImmunosuppressive Agentsbiologicbiological treatmenthealthcare resource utilizationoral immunosuppressantsPsoriasis vulgarisreal-world evidence

Identifiers

PMID38915400
PMCPMC11194666

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.